Breakthrough Treatment for Skin Cancer Curaderm BEC5

Posted on March 13, 2015

Breakthrough Treatment for Skin Cancer, Curaderm BEC5

by Jeffrey Dach MD

A New Discovery Cures Non-Melanoma Skin Cancer

A good friend of mine is an avid outdoor jogger, and he runs a few miles every day in the bright Florida Sun. Unfortunately he is sensitive to the sun, prone to skin cancer, and now has multiple small scars on his face from removal of the skin cancers. In spite of sun protection with a large hat and long sleeve shirt, he requires regular visits to the dermatologist who uses liquid nitrogen to “burn off” the new skin cancers that have appeared since last visit. As a result, he brandishes multiple small scars from each procedure at various places on his face.

Eliminate Skin Cancer Without Scarring

Could there be a better way to eliminate skin cancer without scarring the face? Could there be a medical breakthrough in the treatment of skin cancer? The answer is YES , there is, and it is a skin cream called Cura-Derm or BEC-5 discovered in 1979 and developed by a biochemist in Australia named Bill Cham, PhD.

Observing the Cows in the Field

Dr. Cham’s friend was a veterinarian and he noticed that one of his sick cows recovered from cancer in the eye after rubbing the eye on a Devil’s Apple plant. This piqued his interest so he isolated the active ingredient in the plant which had anti-cancer activity. Eventually, this was made into a skin cream and extensively tested for safety and efficacy. Phase three clinical trials in England showed 78% cure rate during a short study period. Dr Cham says the actual cure rate is higher if treatment is continued longer:

“The dermatologists who conducted the Phase III clinical trials with BEC-5 concluded that BEC5 is a topical preparation, which is safe and effective. BEC5 therapy is ideal for outpatient treatment and is a much needed alternative to surgery for basal cell skin cancer. The clinical trials of BEC5 done by the multi-centres, comprised of application of BEC5 twice daily for eight weeks. Phase III clinical trials involving ten centres in the United Kingdom were completed in 2002. The general success rate of the glycoalkaloid (BEC) cream was 78 percent. Longer duration therapy with BEC would have resulted in higher success rates. ” Quote Dr. Cham.

The cream works exceedingly well with non-melanoma skin cancers such as squamous cell and basal cell which are the common varieties. One advantage is that the cancer “melts away” leaving normal skin with no scarring . Skin cancer involving the lip is an excellent case for the cream since surgery can be disfiguring, while the BEC5 skin cream allows a smoothly healed result.
On average a 20ml bottle of the skin cream can manage one to two large non-melanoma skin cancers, two to three medium sized ones or perhaps twelve sun spots. The bottle costs about 120 dollars. Please note that I have no financial connection with Curaderm or Dr. Cham, and our office does not carry it. However, it is widely available from Dr. Cham and other resellers on the Internet.

Consult Your Dermatologist

Should you wish to try this product, please use it in consultation with your dematologist, of course.
Above video : Introducing Dr Bill Cham on Willesee (an A Current Affair style show) back in the 1980s, talking about his revolution treatment called Curaderm and how it is revolutionising the treatment of skin cancer.
Curaderm BEC5 Eggplant Skin Cancer Cream, an affordable cream, appears to cure and eliminate non-melanoma skin cancers in weeks.

Articles with relates interest:

Skin cancer prevention with green tea.
Cancer as a metabolic disease

References
(1) CuraDerm BE-C5 Bill Cham PhD web site with video of Jonathon Wright and Dr Cham.
(2) Photo Album of Skin Cancer Cases Before and After Treatment on the Curaderm Blog
(3) Case Studies on CuraDerm
(4) Information about CuraDerm
(5) About CuraDerm
(6) Bec5: The Treatment Of Choice,
For Non-Melanoma Skin Cancers By Bill E. Cham, Ph.D.
(7) Interview with Bill Cham
(8) Clinical Research Study BEC5
(9) Cancer Letter 1991 Sep;59(3):183-92. Topical treatment of malignant and premalignant skin lesions by very low concentrations of a standard mixture (BEC) of solasodine glycosides. Cham BE, Daunter B, Evans RA. Department of Medicine, University of Queensland, Australia.
A cream formulation containing high concentrations (10%) of a standard mixture of solasodine glycosides (BEC) has been shown to be effective in the treatment of malignant and benign human skin tumours. We now report that a preparation (Curaderm) which contains very low concentrations of BEC (0.005%) is effective in the treatment of keratoses, basal cell carcinomas (BCCs) and squamous cell carcinomas (SCCs) of the skin of humans. In an open study, clinical and histological observations indicated that all lesions (56 keratoses, 39 BCCs and 29 SCCs) treated with Curaderm had regressed. A placebo formulation had no effect on a smaller number of treated lesions. Curaderm had no adverse effect on the liver, kidneys or haematopoietic system.
(9) Cancer Letter 1987 Aug;36(2):111-8.
Glycoalkaloids from Solanum sodomaeum are effective in the treatment of skin cancers in man. by Cham BE, Meares HM.
A cream formulation containing glycoalkaloids purified from the plant species Solanum sodomaeum L. is effective in the treatment of the malignant human skin tumours; basal cell carcinomas (BCCs), squamous cell carcinomas (SCCs) and the benign tumours; keratoses and keratoacanthomas. Histological analyses of biopsies taken before, during and after treatment give compelling evidence of the efficacy of the formulation. The treated lesions did not recur for at least 3 years after cessation of therapy. The observed complete regressions were; 20/24 for the BCCs; 5/6 for the SCCs; 23/23 for the keratoses; and, 9/9 for the keratoacanthomas. Biochemical, haematological and urinanalytical studies demonstrated that there were no adverse effects on the liver, kidneys or haematopoietic system during treatment. Normal skin treated with the formulation likewise was free from adverse histological or clinical effects. The data indicate that glycoalkaloids of this type are therefore potentially useful in the treatment of several types of human skin cancers.
(11) Cancer Letter 1990 Dec 17;55(3):221-5.
Solasodine glycosides. Selective cytotoxicity for cancer cells and inhibition of cytotoxicity by rhamnose in mice with sarcoma 180. Cham BE, Daunter B. University of Queensland, Department of Medicine, Australia.
BEC, a standard mixture of solasodine glycosides is effective in vivo against murine sarcoma 180 (S180), whereas the aglycone solasodine at equimolar concentrations is ineffective. The efficacy of BEC against S180 in vivo can be inhibited by rhamnose. Mice which are in their terminal stage with S180 can tolerate and become symptom-free of cancer by single dose administration of BEC at concentrations of BEC three times the LD100 for normal mice. These observations suggest that the binding of solasodine glycosides on tumour cells may be mediated through the monosaccharide rhamnose, which forms part of solasonine, solamargine and di-glycosides of solasodine in BEC. Furthermore, these results provide evidence that BEC selectively destroys tumour cells relative to normal cells in vivo.
(12) Cancer Letter 1990 Dec 17;55(3):209-20.
Solasodine glycosides. In vitro preferential cytotoxicity for human cancer cells.
Daunter B, Cham BE. University of Queensland Department of Obstetrics and Gynaecology, Herston, Australia. Solamargine [(22R,25R)-spiro-5-en-3 beta-yl-alpha-L-rhamnopyranosyl- (1—-2glu)-O-alpha-L-rhamnopyranozyl (1—-4glu)-beta-D-glucopyranoze], a glycoside of solasodine preferentially inhibits the uptake of tritiated thymidine by cancer cells. In contrast, solamargine at equivalent concentration, and the mono- and diglycosides of solasodine have a limited effect on the uptake of tritiated thymidine for other cell types, including unstimulated lymphocytes and lymphocytes stimulated with Con A. In contrast the solasodine glycosides do not inhibit the uptake of tritiated thymidine by lymphocytes stimulated with PHA or PWM. The inhibition of tritiated thymidine uptake by solamargine and the mono- and di-glycosides of solasodine are dependent upon their cellular uptake by endogenous endocytic lectins (EELs). The mode of action of the solasodine glycosides, in particular solamargine, appears to be the induction of cell lysis, as determined by morphological examination.
link to this page:http://wp.me/p3gFbV-2GV

Copyright (c) 2007-2015 Jeffrey Dach MD All rights reserved
Click Here for Disclaimer

Jeffrey Dach MD
7450 Griffin Road, Suite 190
Davie, Fl 33314
954-792-4663
http://www.jeffreydachmd.com
http://www.drdach.com
http://www.naturalmedicine101.com
http://www.bioidenticalhormones101.com

Serving Areas of: Hollywood, Aventura, Miami, Fort Lauderdale, Pembroke Pines, Miramar, Davie, Coral Springs, Cooper City, Sunshine Ranches, Hallandale, Surfside, Miami Beach, Sunny Isles, Normandy Isles, Coral Gables, Hialeah, Golden Beach ,Kendall,sunrise, coral springs, parkland,pompano, boca raton, palm beach, weston, dania beach, tamarac, oakland park, boynton beach, delray,lake worth,wellington,plantation